404827-75-4

Basic information

• Product Name: 6-FLUORO-1H-INDAZOL-3-YLAMINE
• Synonyms: 6-FLUORO-1H-INDAZOL-3-YLAMINE;1H-Indazol-3-amine,6-fluoro-(9CI);6-fluoro-1H-indazol-3-aMine
• CAS NO: 404827-75-4
• Molecular Formula: C₇H₆FN₃
• Molecular Weight: 151.14
• Product Categories: HALIDE
• Mol File: 404827-75-4.mol

Chemical Properties

• Boiling Point: 379.288 °C at 760 mmHg
• Flash Point: 183.187 °C
• Appearance: /
• Density: 1.488 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 6-FLUORO-1H-INDAZOL-3-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-FLUORO-1H-INDAZOL-3-YLAMINE(404827-75-4)
• EPA Substance Registry System: 6-FLUORO-1H-INDAZOL-3-YLAMINE(404827-75-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 404827-75-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-FLUORO-1H-INDAZOL-3-YLAMINE is used as a building block for the synthesis of drug candidates due to its versatile chemical properties and potential therapeutic effects.
Used in Medicinal Chemistry Research:
6-FLUORO-1H-INDAZOL-3-YLAMINE is used as a key target for research and development in medicinal chemistry, given its anti-inflammatory and anti-cancer properties, which can be harnessed to create new therapeutic agents.
Used in Organic Chemistry Research:
6-FLUORO-1H-INDAZOL-3-YLAMINE is used as a subject of study in organic chemistry to explore its unique structure and properties, potentially leading to the discovery of novel synthetic pathways and applications.
Used in Anti-inflammatory Applications:
6-FLUORO-1H-INDAZOL-3-YLAMINE is used as an anti-inflammatory agent for its potential to modulate inflammatory responses, which can be beneficial in treating various inflammatory conditions.
Used in Anti-cancer Applications:
6-FLUORO-1H-INDAZOL-3-YLAMINE is used as an anti-cancer agent for its ability to target and inhibit the growth of cancer cells, offering a promising avenue for the development of new cancer therapies.

Upstream product

• 3939-09-1 2,4-difluorobenzonitrile 
• 1219024-63-1 2-[2-(diphenylmethylene)hydrazino]-4-fluorobenzonitrile 

Downstream Products

• 885522-07-6 6-fluoro-3-iodo-1H-indazole 

Relevant articles and documents

Rational Design, Optimization, and Biological Evaluation of Novel MEK4 Inhibitors against Pancreatic Adenocarcinoma

Growth, division, and development of healthy cells relies on efficient response to environmental survival cues. The conserved mitogen-activated protein kinase (MAPK) family of pathways interface extracellular stimuli to intracellular processes for this purpose. Within these pathways, the MEK family has been identified as a target of interest due to its clinical relevance. Particularly, MEK4 has drawn recent attention for its indications in pancreatic and prostate cancers. Here, we report two potent MEK4 inhibitors demonstrating significant reduction of phospho-JNK and antiproliferative properties against pancreatic cancer cell lines. Furthermore, molecular inhibition of MEK4 pathway activates the MEK1/2 pathway, with the combination of MEK1/2 and MEK4 inhibitors demonstrating synergistic effects against pancreatic cancer cells. Our inhibitors provided insight into the crosstalk between MAPK pathways and new tools for elucidating the roles of MEK4 in disease states, findings which will pave the way for better understanding of the MAPK pathways and development of additional probes.

FLUORINE-SUBSTITUTED INDAZOLE COMPOUNDS AND USES THEREOF

Fluorine-substituted indazole compounds, pharmaceutical compositions containing these compounds and uses thereof. The compounds and pharmaceutical compositions can be used as soluble guanylate cyclase simulators.

Α 7 as intranuclear hydroxynicotinic acetylcholine receptor quinuclidines compd.

PROBLEM TO BE SOLVED: To provide ligands for the nicotinic α-7 receptor used for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.SOLUTION: The disclosure provides compounds of the specified formula I, including their salts, and compositions and methods using the compounds.

Compounds as syk kinase inhibitors

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase.

QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

Two-step synthesis of substituted 3-aminoindazoles from 2-bromobenzonitriles

A general two-step synthesis of substituted 3-aminoindazoles from 2-bromobenzonitriles involving a palladium-catalyzed arylation of benzophenone hydrazone followed by an acidic deprotection/cyclization sequence is described. This procedure offers a general and efficient alternative to the typical S NAr reaction of hydrazine with o-fluorobenzonitriles.

PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE

The invention is to provide a novel anticancer agent or sensitizer for cancer chemotherapy or radiotherapy. A compound of a general formula (I): wherein A means an aryl group or a heteroaryl group, or a group of a formula (a):; R1 means a -(C=O)aOb(C1-C6)alkyl group, a -(C=O)aOb(C2-C6)alkenyl group, a -(C=O)aOb(C3-C6)cycloalkyl group, an aryl group or a heteroaryl group; R2 and R3 each mean a hydrogen atom, a halogen atom, a hydroxyl group, a carboxyl group, a -(C=O)aOb(C1-C6)alkyl group or a group of -(C=O)aN(R1e)R2e; R4 means a hydrogen atom or a (C1-C6)alkyl group, and the like have an excellent Wee1-kinase-inhibitory effect, and are therefore useful in the field of medicine, especially in the field of various cancer treatments.

QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

INDAZOLE DERIVATIVES

The invention is concerned with novel indazole derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, X and Y are as defined in the description and in the claims, as well as physiologic